AI in Healthcare? Pfizer, Anthropic, and Longevity Scientists Think It’s Critical

Pfizer, Anthropic, and prominent longevity researchers see AI (artificial intelligence) as the most consequential input shaping healthcare, from molecule design to drug trials and aging research.

Biopharma, frontier model labs, and academic medicine each report meaningful AI-driven progress, although researchers caution that regulation, compute, and biological complexity still set the pace.

Pfizer Reviews an AI-Designed Molecule

Pfizer CEO Albert Bourla said in a Bloomberg TV appearance that the company is reviewing a new molecule its scientists generated using AI.

The remark sits squarely inside Pfizer’s stated strategy. The company has paid up to $350 million to PostEra since 2020 for AI-designed small molecules and antibody-drug conjugate payloads.

In January, they announced a strategic collaboration with the Boltz biomolecular foundation model team to refine open-source models on Pfizer’s internal data.

Pfizer Ventures has previously backed longevity vehicle VitaDAO, reflecting the company’s appetite for AI-adjacent biology bets.

“Once we know the target where we need to hit, we need a medicine to do that. And AI can design medicines and molecules that they can fit that target much faster and better than our own thing,” Bourla stated in a Yahoo Finance interview last November.

Anthropic Claims a Frontier Lead

Speaking at Anthropic’s invite-only financial services event in New York, CEO Dario Amodei said Chinese AI labs are likely 6 to 12 months behind frontier US capabilities, while other US labs trail Anthropic by 1 to 3 months.

The event coincided with the release of Claude Opus 4.7 and a wave of new agents pitched at banks, including a financial-crime tool built with FIS.

Amodei also flagged a closing patching window. He said Anthropic’s Mythos model has surfaced tens of thousands of previously unknown software vulnerabilities.

Based on this, he warns that governments and large enterprises have a six to 12-month window to patch before Chinese models close the gap.

The company’s pre-IPO valuation crossed $1 trillion in April, and Amodei told the audience that first-quarter revenue grew roughly 80 times on an annualized basis.

Longevity Researchers See an Inflection Point

Biomedical gerontologist Aubrey de Grey and immunology professor Derya Unutmaz argued in a new BeInCrypto podcast appearance that AI is now the credible path to reversing aging.

Unutmaz predicted most diseases could be addressed within 10 to 15 years, while de Grey put the odds of reaching longevity escape velocity by the late 2030s at roughly 50 percent.

Subscribe to our YouTube channel to watch leaders and journalists provide expert insights

Unutmaz pushed a sharper line on physician practice in the same conversation.

“Very soon it’s going to be malpractice not to use AI in medicine,” Derya Unutmaz told BeInCrypto.

The week’s three signals point in one direction. Drugmakers, frontier labs, and academic researchers are converging on AI as healthcare’s primary accelerator, while regulators, compute supply, and biological data gaps remain the binding constraints.

Whether Bourla’s molecule advances to trials, Amodei’s lab-gap claim survives independent benchmarking, and the longevity field produces de Grey’s mouse breakthrough will define how fast the field moves through the rest of the decade.

Follow us on X to get the latest news as it happens